Third module of patient partner and researcher training in development
Opportunity for patients and research teams to provide feedback on third imPORTND module ‘Skills for Patient-Oriented Research’
In February 2023, we launched our ‘imPORTND’ platform to offer two online training modules on how to conduct research that is informed by, and most meaningful to, individuals living with neuromuscular disorders. Since the launch we have seen over 100 users access the platform, and we are excited to share that a third training module is currently in development. ‘Skills for Patient-Oriented Research’ includes content on how to develop an effective patient engagement plan, how to share and listen to patient stories, how to work effectively in groups and how to evaluate the project engagement.
Help test the third module
We are currently seeking patients and research team members to test this module and provide feedback on user experience and content relevance. If you or your research team would like to help test the third module, please contact network manager Erin Beattie at <>.
The imPORTND training modules are available for free in both English and French.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.